FATE

Fate Therapeutics, Inc.

2.48 USD

Last updated Sep 4, 20:14 UTC

Yesterday HIGH

$2.5

Yesterday LOW

$2.4

52w HIGH

$3.23

52w LOW

$0.93

EPS

-0.25

PE

-9.92

Next Earnings

Nov 12, 2026

Overview News Insider Transactions Government Trades Fundamentals

Fate Therapeutics, Inc. stock is down -4.62% since 30 days ago. The next earnings date is Nov 12, 2026. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 41.67% of the previous 12 September’s closed higher than August. 67% of analysts rate it a buy.

Benzinga Newsdesk

Wed May 13, 2026

Fate Therapeutics Q1 EPS $(0.26) Beats $(0.28) Estimate, Sales $1.299M Beat $1.139M Estimate

Fate Therapeutics (NASDAQ:FATE) reported quarterly losses of $(0.26) per share which beat the analyst consensus estimate of $(0.28) by 7.14 percent. This is a 18.75 percent increase over losses of $(0.32) per share from
Benzinga Newsdesk

Mon May 11, 2026

Fate Therapeutics To Present Data For Its Off-The-Shelf CAR T-Cell Programs At American Society Of Gene And Cell Therapy Annual Meeting

Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies broadly to
Benzinga Insights

Wed May 6, 2026

10 Health Care Stocks Whale Activity In Today's Session
Benzinga Newsdesk

Tue May 5, 2026

Fate Therapeutics shares are trading higher after the company announced that the FDA has selected FT819 for participation in the Chemistry, Manufacturing, and Controls Development and Readiness Pilot Program for the treatment of moderate to severe systemic lupus erythematosus.
Benzinga Newsdesk

Tue May 5, 2026

Fate Therapeutics' FT819 Selected By FDA As Participant In Chemistry, Manufacturing And Controls Development And Readiness Pilot Program To Treat Moderate To Severe Systemic Lupus Erythematosus

Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies broadly to
Benzinga Newsdesk

Mon May 4, 2026

Fate Therapeutics shares are trading higher after HC Wainwright & Co. maintained its Buy rating on the stock and raised its price target from $5 to $7.
Benzinga Newsdesk

Mon May 4, 2026

Fate Therapeutics Announces That Data From Its Off-The-Shelf CAR T-Cell Programs FT819, FT839 And FT836 Will Be Featured At The American Society Of Gene And Cell Therapy Annual Meeting, May 11–15

Fate Therapeutics will present clinical and translational data from the systemic lupus erythematosus (SLE) arm of its ongoing Phase 1 trial evaluating FT819 in Regimen B, where FT819 is added to background maintenance
Benzinga Newsdesk

Mon May 4, 2026

HC Wainwright & Co. Maintains Buy on Fate Therapeutics, Raises Price Target to $7

HC Wainwright & Co. analyst Robert Burns maintains Fate Therapeutics (NASDAQ:FATE) with a Buy and raises the price target from $5 to $7.
Benzinga Newsdesk

Thu Apr 30, 2026

Fate Therapeutics To Present Clinical Data From Its FT819 Candidate At Congress Of Clinical Rheumatology In Florida

Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with
Benzinga Newsdesk

Thu Apr 16, 2026

Fate Therapeutics Says Preclinical Data From Next-Gen, Off-The-Shelf CAR T-Cell Product Candidate, FT839, To Be Featured At 2026 AACR Annual Meeting

Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with

Piper Sandler

Fri Aug 14, 18:30

buy

confirm
Wells Fargo

Fri Aug 14, 16:56

hold

confirm
Wedbush

Fri Aug 14, 15:08

buy

confirm

Advanced Data Unlock

Cindy Tahl, See Remarks

Tue Aug 4, 2026

FATE Recent Insider Trades and Stock Chart

38,800 shares sold
Bahram Valamehr, President and CEO

Tue Aug 4, 2026

FATE Recent Insider Trades and Stock Chart

43,947 shares sold